1 completed, 1 not yet recruiting, 1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Feng Wang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors - Colorectal Cancer Metastatic | Not yet recruiting | Feng Wang | 200 | 2024-11-15 | 2024-11-12 | |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell Camrelizumab, Apatinib - Esophageal Cancer | Phase 3 | Unknown | Feng Wang | 234 | 2021-12-05 | 2021-09-20 |
| Anlotinib Retrospective Study for Esophageal Cancer Anlotinib - Esophageal Neoplasms | Completed | Feng Wang | 300 | 2019-01-01 | 2022-03-31 |
Bevacizumab (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Tyrosine Kinase Inhibitors (1) · anlotinib (1) · apatinib (1) · camrelizumab (1)
China (1)